# OnCo record thierry-andre (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/thierry-andre/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "thierry-andre" ;
  schema:name "Thierry André"@en ;
  schema:description "Led MOSAIC, which made FOLFOX the adjuvant standard, and KEYNOTE-177, which made pembrolizumab first-line for MSI-high colon cancer."@en ;
  schema:url <https://onco.cc/people/thierry-andre/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=Andre%20T%5BAuthor%5D%20colorectal%20pembrolizumab%20OR%20MOSAIC> ;
  onco:tag "colorectal", "immunotherapy", "adjuvant" ;
  schema:jobTitle "Professor of Medical Oncology, Sorbonne University; Head of Medical Oncology, Hôpital Saint-Antoine, Paris" ;
  onco:cancers <https://onco.cc/cancers/colorectal/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/ctla4/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/> ;
  onco:institutions <https://onco.cc/institutions/iuc-aphp-sorbonne/> ;
  onco:trials <https://onco.cc/trials/keynote-177/>, <https://onco.cc/trials/checkmate-8hw/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-keynote-177-nejm-2020/> ;
  schema:affiliation <https://onco.cc/institutions/iuc-aphp-sorbonne/> .